[Effects of phospholipid hepatoprotective agents in experimental Reye syndrome].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to V N Burkova.
Explore the source record for details and available documents.
In chronic CCl4-hepatitis in rats phospholipid-containing hepatoprotectors, essentiale and eplir differ in their influence on the therapeutic effect of prednisolone; essentiale does not change the antiproliferative effect of the glucocorticoid and weakens its membrane-stabilizing effect, eplir increases these therapeutic effects of prednisolone. Besides, eplir, in distinction from essentiale, reduces lipid accumulation in the liver and hypoproteinemia which are induced by prednisolone.
The administration of eplir (a phospholipid-containing hepatoprotector), as well as of the enterosorbents polyphepan and EST-1 (an agent obtained from dry peat extract), to rats with tetrachloromethane-induced hepatitis protect the liver parenchyma against dystrophy, necrosis, and inflammation, reduce hyperfermentemia, decrease the blood bilirubin, ammonia, phenols, and malonaldehyde, and increase the urea content in blood serum, while not fully restoring all these biochemical parameters on the normal level. The treatment of rats with toxic hepatitis by a combination of eplir and enterosorbents is accompanied by a synergistic increase in the therapeutic efficacy of each component, leading to normalization of the biochemical parameters reflecting the functional slate of liver.
The experiments on rats with a model toxic liver damage (tetrachloromethane hepatitis) showed evidence of a high hepatoprotector activity of liproxol, representing a combination of eplir and lokhein mixed in a 1-12 ratio. Liproxol inhibits lipid peroxidation, stimulates the excretory and detoxicant functions of liver, reduces hyperfermentation, and normalized membrane phospholipid composition.
The results of experiments on white rats with CCl4-induced hepatitis showed that the combined introduction of cyclophosphamide and hepatoprotectors of the plant origin (lochein, maksar, silimarin) leads to a decrease in acute toxicity and to less pronounced manifestations of hepatotoxicity of cyclophosphamide. Hepatoprotectors decrease the activity of aminotransferases, reduce the level of bilirubin, normalize the content of protein andpipids in the blood serum, and suppress the development of morphological disorders in the liver.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.